Emocog Setting The Standard For Cognitive Decline DTx in Korea
World-First Pivotal Trial Underway
Executive Summary
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.
You may also be interested in...
Released: Germany’s Digital Strategy Will Transform Health And Care
An intense period of work overseen by Germany’s health ministry has culminated in the release of a new digital health care strategy. Germany now has a clear direction for how care will be transformed, says e-health chief Sebastian Zilch.
Aimmed’s Insomnia App Approved As Korea’s First Digital Therapeutic
More approvals of digital therapeutics are expected to come in the wake of South Korea's first approval of this type of product, Aimmed’s insomnia mobile app Somzz. But reimbursement decisions on such therapies could take months and will be closely monitored going forward.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.